Deprizine Side Effects
Generic Name: ranitidine
Note: This document contains side effect information about ranitidine. Some of the dosage forms listed on this page may not apply to the brand name Deprizine.
For the Consumer
Applies to ranitidine: oral solution, oral tablets and tablets for, oral tablets effervescent for solution, parenteral injection, parenteral injection for iv infusion only
Side effects include:
Oral or parenteral therapy: Headache, sometimes severe.
IM therapy: Transient pain at injection site.
IV therapy: Transient local burning or itching.
For Healthcare Professionals
Applies to ranitidine: compounding powder, injectable solution, intravenous solution, oral capsule, oral granule effervescent, oral syrup, oral tablet, oral tablet effervescent
The most commonly reported side effect for IM administration was injection site pain, and the most commonly reported side effects with IV administration were localized pain and burning.[Ref]
Bradycardia, atrioventricular block, tachycardia, and asystole have occurred in H2 receptor antagonists.[Ref]
Headache may be related to administration of treatment.[Ref]
Very rare (less than 0.01%): Musculoskeletal symptoms, arthralgia, myalgia[Ref]
Rare (0.01% to 0.1%): Transient and reversible changes in liver function tests, increased ALT levels
Very rare (less than 0.01%): Hepatocellular/hepatocanalicular/mixed hepatitis with/without jaundice[Ref]
Hepatitis with/without jaundice were usually reversible.
ALT levels increased to at least 2 times the pretreatment levels in patients receiving high IV doses for at least 5 days.[Ref]
Anaphylactic shock occurred after administration of a single dose.[Ref]
Rare (0.01% to 0.1%): Elevation in serum creatinine
Very rare (less than 0.01%): Acute interstitial nephritis[Ref]
Elevation in serum creatinine was usually slight, and typically normalized with continued treatment.[Ref]
Rare (0.01% to 0.1%): Reversible blurred vision[Ref]
Very rare (less than 0.01%): Blood count changes, leukopenia, thrombocytopenia, granulocytopenia, agranulocytosis, pancytopenia, marrow hypoplasia/aplasia
Frequency not reported: Aplastic anemia, immune hemolytic anemia/acquired immune hemolytic anemia, eosinophilia[Ref]
Leukopenia, granulocytopenia, and thrombocytopenia were usually reversible.[Ref]
Very rare (less than 0.01%): Gynecomastia[Ref]
Frequency not reported: Injection site pain, transient localized burning or itching[Ref]
1. "Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals, New York, NY.
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
4. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
More about Deprizine (ranitidine)
- Deprizine Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews – Add your own review/rating
- Drug class: H2 antagonists